Brought to you by 
Drug discovery company Recursion Pharmaceuticals raises $60mm in Series B financing
22 Apr 2022
Executive Summary
Recursion Pharmaceuticals LLC (drug discovery) raised $60mm in its Series B financing round led by Data Collective (also adds a board seat), with participation from all prior institutional investors such as Series A lead Lux Capital, Obvious Ventures, Advantage Capital, Felicis, Epic, and AME, and new investors Mubadala, Menlo Ventures, CRV, Two Sigma, and High-Value Angel Investors.
Deal Industry
- In Vitro Diagnostics
- Pharmaceuticals
-
Digital Health
- Artificial Intelligence
-
Biotechnology
-
Drug Discovery Tools
- Bioinformatics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Drug discovery company Recursion Pharmaceuticals raises $60mm in Series B financing
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice